InvestorsHub Logo
Followers 139
Posts 23822
Boards Moderated 0
Alias Born 04/08/2004

Re: TempePhil post# 297189

Saturday, 02/06/2021 7:10:22 PM

Saturday, February 06, 2021 7:10:22 PM

Post# of 471267
There will be no need for another Phase 3 trial for ANAVEX2-73 for Treatment of Early Alzheimer's Disease the current Phase 2/3 trial is and will be sufficient for regulatory approval. All we need is very good p values when comparing the active drug cohorts (Anavex 2-73) with the placebo cohort. The trial size is already part of the p value and power calculation.





https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167374/

There will be no need for another Phase 3 trial for ANAVEX2-73 for Treatment of Early Alzheimer's Disease the current Phase 2/3 trial is and will be sufficient for regulatory approval.

Good luck and GOD bless
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News